close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

26.88 -0.54 (-1.97%)
Streaming Delayed Price Updated: 3:54 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 Next >
News headline image
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office... 
Via The Motley Fool
Topics Regulatory Compliance
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Alto Neuroscience Inc (NYSE:ANRO) Reports Narrower Q3 2025 Loss and Accelerated Pipeline Progress ↗
Alto Neuroscience reports a narrower-than-expected Q3 2025 loss and advances its precision psychiatry pipeline, with cash extending into 2028. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Gapping stocks in Monday's session ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug ↗
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
Alto Neuroscience Posts Q2 Net Loss ↗
Via The Motley Fool
News headline image
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal ↗
Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207. 
Via Benzinga
News headline image
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock ↗
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 
Via Stocktwits
News headline image
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Nasdaq Down 2%; US Crude Stocks Increase ↗
 
Via Benzinga
News headline image
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform ↗
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies. 
Via Benzinga
News headline image
Gold Moves Lower; AT&T Earnings Top Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss ↗
 
Via Benzinga
Topics Stocks
News headline image
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024 ↗
ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On ↗
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors. 
Via InvestorPlace
News headline image
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 ↗
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.